Advances in the Use of PET/CT and MRI in Prostate Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 894
Special Issue Editor
Special Issue Information
Dear Colleagues,
The early detection of lymph node and distant organ metastases from prostate cancer at initial staging, especially for restaging when persistence or recurrence is suspected, represents one of the most interesting challenges in modern medicine. The most recent advancements in PET/CT and MRI serve this purpose well, thanks to the development of even higher performing and more specific radiopharmaceuticals for PET/CT imaging, along with the use of multi-parametric MRI, including diffusion-weighted and post-contrast dynamic sequences and spectroscopy. An even earlier definition of overall disease status enables the application of the most correct treatment for the individual patient, with an undeniable impact on prognosis.
This Special Issue, entitled “Advances in the Use of PET/CT and MRI in Prostate Cancer”, will focus on the role of the most recent advancements in PET/CT and MRI in the management of patients affected by prostate cancer, for initial staging and restaging purposes. Moreover, the advanced analysis of PET/CT and MRI using radiomics enables the extraction of otherwise concealed information from images, potentially useful for therapeutic and diagnostic management. Finally, PET/CT may act as guidance to provide indications for therapy with novel receptor-targeted radiopharmaceuticals and to assess its effectiveness.
Dr. Carmelo Caldarella
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PET/CT
- MRI
- prostate cancer
- radiomic
- receptor-targeted radiopharmaceuticals
